Design of Carbon based nanoplatform to Target pancreatic cancer
Dr. Sofia Dominguez
Dr. Sofia Dominguez was awarded with an IRC Enterprise Partnership Scheme fellowship in partnership with Breakthrough Cancer Research. Sofia is working in Prof. Silvia Giordani’s lab at Dublin City University.
According to the National Cancer Registry, more than 600 people are diagnosed with pancreatic cancer in Ireland annually, with approximately 530 dying every year. The 5-year survival rate following a pancreatic cancer diagnosis is just 10%.
Over the last decade, novel therapeutic approaches have sought to cure patients offering specially adapted therapies and alternatives when classic treatments like surgery, chemotherapy, and radiotherapy are not sufficient and cause adverse effects. We propose nanomedicine, which is a sub-field of medicine that focuses on applying nanotechnology and nano-sized tools, allowing a better, more stable and controlled delivery of the active ingredient, or drug to the tumour. This research promises an improvement in the therapeutic efficacy of the anti-cancer treatments while reducing the doses administered, and consequently the short- and long-term side effects.
RESEARCH FINDINGS
Conference Presentations
BenBedPhar COST Scientific Meeting 2024, Tallinn. Title: “Environmentally friendly synthesis of Carbon Dots for cancer therapy”
9th EuChemS Chemistry Congress (ECC-9) 2024, Dublin. Title: “Environmentally friendly synthesis of Carbon Dots”
Back
Start year
2023
End year
2025
Principal Investigator
Prof. Silvia Giordani
Researcher
Dr. Sofia Dominguez
Institution
Dublin City University
Grant Funding
IRC Enterprise Partnership Scheme in partnership with Breakthrough Cancer Research
Linked Breakthrough Research Priorities
Increase research investment into poor prognosis cancers and currently incurable cancers prioritising lung, oesophageal, ovarian, pancreatic, brain, liver and stomach cancers.
Fund research which aims to improve the effectiveness or specificity of current cancer therapies including investing in biomarkers discovery, nutrition and therapeutic delivery.